ciprofloxacin has been researched along with Lung Diseases, Interstitial in 5 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Similar effects were observed in SSc-interstitial lung disease (ILD) lung fibroblasts." | 1.38 | Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. ( Bujor, AM; Christmann, RB; Haines, P; Junie, M; Lafyatis, R; Padilla, C; Sampaio-Barros, PD; Trojanowska, M, 2012) |
| "Ciprofloxacin can induce interstitial pneumonitis with acute respiratory failure." | 1.32 | Ciprofloxacin-induced acute interstitial pneumonitis. ( Bubendorf, L; Leuppi, JD; Oberholzer, M; Steiger, D; Tamm, M, 2004) |
| "Rhabdomyolysis and acute renal failure were successfully treated by transfusion, diuretic therapy, and glucocorticoid therapy." | 1.32 | [Surviving case of Legionella pneumonia showing a high level of serum KL-6 and complicated with rhabdomyolysis]. ( Kawai, A; Nakajima, H; Nakajima, S; Sawaguchi, H; Touda, Y, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Meng, J | 1 |
| Cao, L | 1 |
| Li, Y | 1 |
| Deng, P | 1 |
| Pan, P | 1 |
| Hu, C | 1 |
| Yang, H | 1 |
| Hantz, S | 1 |
| Garnier, F | 1 |
| Peuchant, O | 1 |
| Menetrey, C | 1 |
| Charron, A | 1 |
| Ploy, MC | 1 |
| Bébéar, C | 1 |
| Pereyre, S | 1 |
| Bujor, AM | 1 |
| Haines, P | 1 |
| Padilla, C | 1 |
| Christmann, RB | 1 |
| Junie, M | 1 |
| Sampaio-Barros, PD | 1 |
| Lafyatis, R | 1 |
| Trojanowska, M | 1 |
| Steiger, D | 1 |
| Bubendorf, L | 1 |
| Oberholzer, M | 1 |
| Tamm, M | 1 |
| Leuppi, JD | 1 |
| Kawai, A | 1 |
| Nakajima, H | 1 |
| Sawaguchi, H | 1 |
| Touda, Y | 1 |
| Nakajima, S | 1 |
5 other studies available for ciprofloxacin and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Synthesis and investigations of ciprofloxacin loaded engineered selenium lipid nanocarriers for effective drug delivery system for preventing lung infections of interstitial lung disease.
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Bacterial Infections; Catalase; Ciprofloxacin; Drug Ca | 2019 |
Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child.
Topics: Anti-Bacterial Agents; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Lung Diseases, Inte | 2012 |
Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
Topics: Cartilage Oligomeric Matrix Protein; Case-Control Studies; Cells, Cultured; Ciprofloxacin; Collagen | 2012 |
Ciprofloxacin-induced acute interstitial pneumonitis.
Topics: Acute Disease; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Lung Diseases, Interstiti | 2004 |
[Surviving case of Legionella pneumonia showing a high level of serum KL-6 and complicated with rhabdomyolysis].
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Antibodies, Bacterial; Antigens; Antigens, Bacteri | 2004 |